News of Note—GlaxoSmithKline, Ebola and SK Bioscience

newspaper
In this week's news of note, the World Health Organization declared an end to the Ebola outbreak in Congo. (Pixabay)

Here is some other vaccine news of note for the week.

> GlaxoSmithKline has reported £1.25 billion ($1.65 billion) in second-quarter vaccine sales, a 16% increase at constant currencies. Reuters story

> The World Health Organization has declared an end to the Ebola outbreak in the Democratic Republic of Congo. Release

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.

> South Korea's SK Bioscience is spending $89 million on a plant to increase vaccine capacity. Pulse story

Read more on
Ebola GlaxoSmithKline Shingrix